Results 111 to 120 of about 2,138,197 (387)

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Intravascular large B-cell lymphoma

Przegląd Dermatologiczny, 2021
Agnieszka Odziomek, Piotr Jarliński, Ewelina Rebizak, Jolanta Węgłowska   +3 more
doaj   +1 more source

Classical Hodgkin’s lymphoma shows epigenetic features of abortive plasma cell differentiation

Haematologica, 2011
Background Epigenetic changes are involved in the extinction of the B-cell gene expression program of classical Hodgkin’s lymphoma. However, little is known regarding epigenetic similarities between cells of classical Hodgkin’s lymphoma and plasma cell ...
Volkhard Seitz, Philippe E. Thomas, Karin Zimmermann, Ulrike Paul, Anke Ehlers, Maria Joosten, Lora Dimitrova, Dido Lenze, Anke Sommerfeld, Elisabeth Oker, Ulf Leser, Harald Stein, Michael Hummel   +12 more
doaj   +1 more source

Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers.: CYCLON-induced Rituximab resistance [PDF]

, 2013
International audienceImmuno-chemotherapy elicit high response rates in B-cell non-Hodgkin lymphoma but heterogeneity in response duration is observed, with some patients achieving cure and others showing refractory disease or relapse.
Alexandra Debernardi, Anouk Emadali, Benoit Bernay, Carlo Petosa, Charles E. McKenna, Christophe Bruley, Claire Rome, Dominique Leroux, Elena Ferri, Florence Combes, Friedberg JW, Juliana Bruder‐Costa, Jérôme Garin, Kato M, Mary B. Callanan, Myriam Ferro, Patricia Betton, Rousseaux S, Rémy Gressin, Saadi Khochbin, Samuel Duley, Sieme Hamaidia, Sophie Rousseaux, Swerdlow SH, Sylvie Kieffer‐Jaquinod   +24 more
core   +4 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma

Hematology Reports, 2011
The determination of prognosis for B-Non- Hodgkin’s lymphoma (NHL) is known to be related to the multiple differences in tumor cell biology. Bcl-2 and Bcl-6 are two markers linked to germinal center B cells.
Hanan Mohamed Mahmoud, Yasmin Nabil Elsakhawy   +1 more
doaj   +1 more source

Human leukocyte antigens and genetic susceptibility to lymphoma [PDF]

, 2015
Familial aggregation, coupled with ethnic variation in incidence, suggests that inherited susceptibility plays a role in the development of lymphoma, and the search for genetic risk factors has highlighted the contribution of the human leukocyte antigen (
Jarrett, R.F., McAulay, K.A.
core   +1 more source

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma

Protein & Cell, 2020
Immunotherapy has been applied successfully to treat B-cell lymphomas in preclinical models or clinical settings. However, immunotherapy resistance is a major challenge for B-cell lymphoma treatment.
Xiaoguang Wang, B. Waschke, Rachel A. Woolaver, Samantha M. Y. Chen, Zhangguo Chen, Jing H. Wang   +5 more
semanticscholar   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation [PDF]

, 2019
B cell lymphoma-6 (BCL6) is highly expressed in germinal center B cells, but how its expression is maintained is still not completely clear. Aryl hydrocarbon receptor interacting protein (AIP) is a cochaperone of heat shock protein 90. Deletion of Aip in
Allen, Baron, Basso, Bedekovics, Boulianne, Bunting, Caimari, Calado, Capasso, Cerami, Cerchietti, Culjkovic-Kraljacic, Dent, Dominguez-Sola, Duan, Duy, García de Vinuesa, Hernández-Ramírez, Hertlein, Huang, Hussain, Kazlauskas, Komander, Kriegenburg, Kutner, Lee, Lees, Leontiou, Li, Manjarrez, Mesin, Meyer, Morales, Niu, Paul, Perrody, Phan, Polier, Sander, Sato, Schneider, Schopf, Stockinger, Taipale, Taipale, Trepel, Trivellin, Vaidyanathan, Veldhoen, Victora, Victora, Vierimaa, Villa, Weigert, Whitesell, Ye, Zong   +56 more
core   +4 more sources